Kazue Masuko
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb.
Journal: FEBS open bio
Published: August 22, 2024
CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2/CD98 antibody inhibits the growth signal of human breast cancer cells.
Journal: Genes to cells : devoted to molecular & cellular mechanisms
Published: January 09, 2023
Dual-targeting therapy against HER3/MET in human colorectal cancers.
Journal: Cancer medicine
Published: August 08, 2022
Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs.
Journal: Biochemical and biophysical research communications
Published: August 27, 2021
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target.
Journal: Oncotarget
Published: April 26, 2021
Anti-tumor effects of an antagonistic mAb against the ASCT2 amino acid transporter on KRAS-mutated human colorectal cancer cells.
Journal: Cancer medicine
Published: March 30, 2019
Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.
Journal: Cancer science
Published: September 20, 2018
Inhibition of tumor formation and metastasis by a monoclonal antibody against lymphatic vessel endothelial hyaluronan receptor 1.
Journal: Cancer science
Published: April 23, 2018
Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells.
Journal: Biochemical and biophysical research communications
Published: January 05, 2016
Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET.
Journal: PloS one
Published: June 23, 2013
Last Updated: 09/26/2026